The first donor-derived cell-free DNA test to assess allograft health in kidney transplant patients is also beneficial for repeat transplant recipients, a new study finds.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with screenings and increase detection rates.
A study from Mayo Clinic researchers shows less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016, which is below the 81% screening compliance rate self-reported in the 2015 National Health Interview Survey.
The two companies will look at advancing the development and commercialization of diagnostic tests for early detection of the disease.
An initiative at Nottingham University Hospital in Nottingham, England is making it easier for pediatric transplant patients and their caregivers to collect blood samples at home for therapeutic drug monitoring.
A team from Brigham and Women’s Hospital are developing a test that can detect tau protein, a calling card for Alzheimer’s disease.
The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
Daxor’s new technology designed to measure blood volume has the potential to reduce patient readmission rates and improve outcomes for patients suffering from acute heart failure.
Doctors need more tools to quickly determine whether an antibiotic is truly needed, an expert tells MD+DI.
A startup spawned from Oxford University is trying to commercialize components of a quantum computing technology that could ultimately improve the downstream end of existing diagnostic devices.
The Madison, WI-based company said its test can identify metabolic subtypes associated with the Autism Spectrum and can be used to screen children as young as 18 months.
Diagnostics manufacturer OpGen is partnering with ILUM and the NY State Department of Health to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide.